Go Pro
→ Analyst nicknamed “The Prophet” issues new warning for America (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Genocea Biosciences, Inc. stock logo
GNCAQ
Genocea Biosciences
$0.00
$0.00
▼
$0.00
$5K2.441,863 shsN/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
$0.00
$0.00
$0.00
▼
$0.01
$17K-0.223,962 shs32,052 shs
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
$0.00
$0.00
$0.00
▼
$0.02
$11K1.3115,534 shs30,100 shs
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
$0.01
$0.00
▼
$0.10
$14K-16.551,322 shs14 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Genocea Biosciences, Inc. stock logo
GNCAQ
Genocea Biosciences
0.00%0.00%0.00%0.00%0.00%
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
-33.33%-33.33%0.00%-33.33%+33.33%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
0.00%0.00%+300.00%+300.00%+300.00%
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
0.00%+11,000.00%+5,450.00%0.00%-55.78%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Genocea Biosciences, Inc. stock logo
GNCAQ
Genocea Biosciences
$0.00
$0.00
▼
$0.00
$5K2.441,863 shsN/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
$0.00
$0.00
$0.00
▼
$0.01
$17K-0.223,962 shs32,052 shs
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
$0.00
$0.00
$0.00
▼
$0.02
$11K1.3115,534 shs30,100 shs
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
$0.01
$0.00
▼
$0.10
$14K-16.551,322 shs14 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Genocea Biosciences, Inc. stock logo
GNCAQ
Genocea Biosciences
0.00%0.00%0.00%0.00%0.00%
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
-33.33%-33.33%0.00%-33.33%+33.33%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
0.00%0.00%+300.00%+300.00%+300.00%
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
0.00%+11,000.00%+5,450.00%0.00%-55.78%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Genocea Biosciences, Inc. stock logo
GNCAQ
Genocea Biosciences
0.00
N/AN/AN/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
0.00
N/AN/AN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
0.00
N/AN/AN/A
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Genocea Biosciences, Inc. stock logo
GNCAQ
Genocea Biosciences
N/AN/AN/AN/AN/AN/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
N/AN/AN/AN/AN/AN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
$386K0.03N/AN/A$0.79 per share0.00
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
N/AN/AN/AN/A$1.65 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Genocea Biosciences, Inc. stock logo
GNCAQ
Genocea Biosciences
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
-$11.61MN/AN/AN/AN/AN/AN/AN/A12/2/2026 (Estimated)
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
-$164.57M-$3.03N/AN/AN/AN/A-3,369.56%-97.04%10/29/2026 (Estimated)
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
-$15.19M-$123.25N/AN/AN/AN/A-1,554.34%-338.29%11/19/2026 (Estimated)
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Genocea Biosciences, Inc. stock logo
GNCAQ
Genocea Biosciences
N/AN/AN/AN/AN/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
N/AN/AN/AN/AN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
N/AN/AN/AN/AN/A
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Genocea Biosciences, Inc. stock logo
GNCAQ
Genocea Biosciences
N/AN/AN/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
N/AN/AN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
N/A
2.25
2.25
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
N/A
0.13
0.13

Institutional Ownership

CompanyInstitutional Ownership
Genocea Biosciences, Inc. stock logo
GNCAQ
Genocea Biosciences
N/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
N/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
91.47%
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
32.23%

Insider Ownership

CompanyInsider Ownership
Genocea Biosciences, Inc. stock logo
GNCAQ
Genocea Biosciences
1.61%
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
5.10%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
12.26%
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
3.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Genocea Biosciences, Inc. stock logo
GNCAQ
Genocea Biosciences
7053.02 millionN/ANot Optionable
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
1342.08 million39.94 millionNot Optionable
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
6826.83 million23.54 millionNo Data
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
21.24 million4.71 millionNot Optionable

Recent News About These Companies

Virpax Pharmaceuticals stock plummets on Nasdaq delisting news
April 3, 2025  |  investing.comhttps://www.investing.com/news/stock-market-news/virpax-pharmaceuticals-stock-plummets-on-nasdaq-delisting-news-93CH-3966072
Virpax Pharmaceuticals Inc trading halted, news pending
March 21, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/virpax-pharmaceuticals-inc-trading-halted-news-pending-1034500708
Virpax reports positive results in Probudur dog study
March 20, 2025  |  investing.comhttps://www.investing.com/news/company-news/virpax-reports-positive-results-in-probudur-dog-study-93CH-3935131
Virpax receives positive Probudur results for dose range study
March 20, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/virpax-receives-positive-probudur-results-for-dose-range-study-1034490634
Virpax Pharmaceuticals announces 1-for-25 reverse stock split
March 20, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/virpax-pharmaceuticals-announces-1-for-25-reverse-stock-split-1034494202
Virpax Receives Positive Probudur™ Results for Dose Range Study Moves Towards Next Steps in IND
March 18, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/virpax-receives-positive-probudur-results-200100643.html
Virpax Pharmaceuticals files to sell common stock and warrants, no amount given
March 18, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/virpax-pharmaceuticals-files-to-sell-common-stock-and-warrants-no-amount-given-1034485903
Virpax Pharmaceuticals Explores Intranasal mRNA Vaccine Delivery Using MET
March 11, 2025  |  msn.comhttps://www.msn.com/en-us/health/other/virpax-pharmaceuticals-explores-intranasal-mrna-vaccine-delivery-using-met/ar-AA1AGDwC
Virpax Pharmaceuticals to Present NES100 Toxicity Study at Major Toxicology Conference
March 11, 2025  |  msn.comhttps://www.msn.com/en-us/health/other/virpax-pharmaceuticals-to-present-nes100-toxicity-study-at-major-toxicology-conference/ar-AA1AF8g0
Virpax Looking to Use MET to Develop Intranasal COVID Vaccine
March 7, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250307334228/en/virpax-looking-to-use-met-to-develop-intranasal-covid-vaccine/
Analysts Conflicted on These Healthcare Names: Clearside Biomedical (CLSD) and Virpax Pharmaceuticals (VRPX)
March 6, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/analysts-conflicted-on-these-healthcare-names-clearside-biomedical-clsd-and-virpax-pharmaceuticals-vrpx-1034450215
Virpax’s NES100 to be Presented at The Society of Toxicology by NCATS
March 5, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/virpax-nes100-presented-society-toxicology-210100662.html
Virpax Pharmaceuticals Applauds Successful Trial of Molecular Envelope Technology
March 3, 2025  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/virpax-pharmaceuticals-applauds-successful-trial-of-molecular-envelope-technology/ar-AA1A7VRw
Virpax lauds Nanomerics’ MET study with no severe side effects
March 1, 2025  |  investing.comhttps://www.investing.com/news/company-news/virpax-lauds-nanomerics-met-study-with-no-severe-side-effects-93CH-3897728
Virpax Reports Positive Results in Human Study for its Molecular Envelope Technology
February 27, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/virpax-reports-positive-results-human-210100424.html
Virpax Reports Positive Results in Human Study for its Molecular Envelope Technology
February 27, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250227128970/en/virpax-reports-positive-results-in-human-study-for-its-molecular-envelope-technology/
Virpax Confirms Positive Results with US Army with Probudur™ for Combat Care Study
February 13, 2025  |  joplinglobe.comJ
Virpax Pharmaceuticals confirms results with U.S. Army with Probudur
February 13, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/virpax-pharmaceuticals-confirms-results-with-u-s-army-with-probudur-1034358717
Virpax reports positive study results for pain management drug
February 13, 2025  |  msn.comhttps://www.msn.com/en-us/money/general/virpax-reports-positive-study-results-for-pain-management-drug/ar-AA1z0EUb
Virpax Pharmaceuticals appoints new independent director
February 6, 2025  |  msn.comhttps://www.msn.com/en-us/money/general/virpax-pharmaceuticals-appoints-new-independent-director/ar-AA1yywrg

New MarketBeat Followers Over Time

Media Sentiment Over Time

Genocea Biosciences stock logo

Genocea Biosciences NASDAQ:GNCAQ

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts. The plan was later approved as Chapter 11 liquidation on May 11, 2023.

Scopus BioPharma stock logo

Scopus BioPharma NASDAQ:SCPS

$0.0004 0.00 (0.00%)
As of 09/23/2026 10:24 AM Eastern

Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses. The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein. Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.

Syros Pharmaceuticals stock logo

Syros Pharmaceuticals NASDAQ:SYRS

$0.0004 0.00 (0.00%)
As of 03:37 PM Eastern

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

Virpax Pharmaceuticals stock logo

Virpax Pharmaceuticals NASDAQ:VRPX

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas